黑素瘤免疫检查点抑制剂治疗相关的生物标志物研究进展

Biomarkers related to the treatment of melanoma with immune checkpoint inhibitors

近年来免疫检查点抑制剂在黑素瘤的治疗中取得了突破性的进展。但是只有一小部分患者对免疫治疗有持久反应,且随着联合用药的出现,免疫相关不良事件的风险和耐药性也在增加。本文对黑素瘤免疫检查点抑制剂疗效标志物的研究进展作一综述,期望通过精准的预测标志物来筛选免疫治疗的获益人群,指导个体化临床治疗,降低耐药性及不良反应。

Recently,great breakthroughs have been made in immune checkpoint inhibitors for the treatment of melanoma.However,only a small proportion of patients show a long-lasting response to immunotherapy,and risks of immune-related adverse events and drug resistance have been also increasing along with the emergence of combination treatment.This review summarizes biomarkers related to the efficacy of immune checkpoint inhibitors in the treatment of melanoma,aiming to predict and screen out patients who may benefit from immunotherapy,guide individualized clinical treatment,and reduce the occurrence of drug resistance and adverse reactions.